2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
1University of Illinois at Chicago, Chicago, IL, 2Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…2022 American Transplant Congress
Variation in Immunosuppressive Regimen in Children Receiving Liver Transplants: An Analysis of the UNOS Database
*Purpose: Optimizing immunosuppression (IS) was identified as a priority for pediatric liver transplant (LT) families and providers in the Starzl Network, a multi-center learning health…2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…2022 American Transplant Congress
Impact of Respiratory Viral Panel Testing on Clinical Decision-Making Among Lung Transplant Recipients Based on Extent of Immunosuppression
*Purpose: Lung transplant recipients (LTRs) are at high risk for complications from viral respiratory infection, including chronic allograft dysfunction. Thus, multiplex molecular testing for respiratory…2022 American Transplant Congress
Longitudinal Characterization of the Microvirome in a Cohort of Renal Transplant Recipients
*Purpose: The selective targeting of T cells in transplant immunosuppression medications leads to a high rate of viral infections, with different immunosuppression regimens resulting in…2022 American Transplant Congress
Outcomes of a Novel Belatacept-Based Regimen – Beyond 2 Years of Follow-Up
*Purpose: For kidney transplant recipients (KTR) there are limited choices of immunosuppression (IS) maintenance regimens. The most commonly used regimen consists of a calcineurin inhibitor…2022 American Transplant Congress
Early Experience with 4-drug Maintenance Immunosuppression in Kidney and Pancreas Transplant Recipients
*Purpose: Belatacept based immunosuppression regimens in kidney transplant recipients have been associated with better kidney function, improved metabolic profile, less de novo DSA formation and…2022 American Transplant Congress
COVID-19 Syndrome After Liver Transplant: Immunosuppression Role and Risk Factors for Mortality
*Purpose: Data on mortality and immunosuppression role regarding Liver transplant recipients affected by COVID-19 are still under debate. The present study identified risk factors for…2022 American Transplant Congress
Disruption of B Cell Population is Associated with Increased Infections in Pediatric Transplant Recipients
Pediatrics, UCSD Rady Children's, San Diego, CA
*Purpose: Solid-organ transplant recipients are placed on long-term immunosuppression, preventing graft rejection but increasing the risk of infection. Pediatric transplant recipients are at increased risk…2022 American Transplant Congress
Accepting Rejection in Liver Transplant Recipients Requiring Renal Replacement Therapy: A Practice Paradigm
*Purpose: The purpose of this study is to evaluate rejection outcomes in those requiring renal replacement therapy (RRT) after liver transplant.*Methods: This was a single…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 138
- Next Page »